Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    GGP-57148B

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inhibikase Starts Enrollment in Global Phase 3 IMPROVE-PAH Trial
    Inhibikase Starts Enrollment in Global Phase 3 IMPROVE-PAH Trial

    07 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/07/3269056/0/en/Inhibikase-Therapeutics-Announces-Enrollment-of-First-Patient-in-IMPROVE-PAH-Global-Phase-3-Study-of-IKT-001-in-the-Treatment-of-Pulmonary-Arterial-Hypertension.html

    GLOBENEWSWIRE
    07 Apr 2026
    Share Share
    Shorla Expands U.S. Presence With Sales, Market Access Teams
    Shorla Expands U.S. Presence With Sales, Market Access Teams

    04 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250304027981/en

    BUSINESSWIRE
    04 Mar 2025
    Share Share
    Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI
    Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

    28 Nov 2024

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/shilpa-medicares-jv-oncosol-gets-usfda-approval-for-imkeldi-16490

    INDPHARMAPOST
    28 Nov 2024
    Share Share
    Shorla gains FDA nod for 1st oral version of Novartis' Gleevec
    Shorla gains FDA nod for 1st oral version of Novartis' Gleevec

    27 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241125044117/en/Shorla-Oncology-Announces-FDA-Approval-of-IMKELDI-imatinib-Oral-Solution-an-Oral-Liquid-for-the-Treatment-of-Certain-Forms-of-Leukemia-and-Other-Cancers

    BUSINESSWIRE
    27 Nov 2024
    Share Share
    Kura Oncology Reports Preclinical Data For Ziftomenib In GIST
    Kura Oncology Reports Preclinical Data For Ziftomenib In GIST

    24 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/10/24/2968596/35186/en/Kura-Oncology-Reports-Preclinical-Data-Supporting-Opportunity-for-Ziftomenib-in-Treatment-of-Gastrointestinal-Stromal-Tumors-GIST.html

    GLOBENEWSWIRE
    24 Oct 2024
    Share Share
    Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST
    Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926821/35186/en/Kura-Oncology-Announces-FDA-Clearance-of-IND-Application-for-Menin-Inhibitor-Ziftomenib-in-Advanced-Gastrointestinal-Stromal-Tumors-GIST.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.